✨ Your Portfolio is fetched and updated from zerodha.
Small Pharmaceuticals
Market Cap
₹3,549 Cr.
P/E
57.37

Key Ratios

Market cap
Market cap
3,549 Cr
PE
PE
57.37
Prom Holding
Prom Holding
72.52 %
ROE (%)
ROE (%)
16.17
ROCE (%)
ROCE (%)
18.19
Div Yield (%)
Div Yield (%)
0.06
Sales
Sales
840 Cr
OPM (%)
OPM (%)
15.73 %
Debt to Equity
Debt to Equity
0.60

About

Gufic Biosciences Limited is a public company domiciled in India and is incorporated under the… Read more
Low
299
52W Range
High
504
  • Gufic Biosciences
  • Orchid Pharma
  • Unichem Lab
  • TJI Pharma - Small Cap

Timeline

Dividend Update Board Meeting Financials

Key company specific updates

Custom financial statement

New
Edit rows

Forensics

8 Yes

Positive for this company

2 Neutral

Neutral for this company

7 No

Negative for this company

0 No Data

Insufficient data to analyse

Market Share

0.05 %
(as of Jul 22)
Anti-Infectives - Market Share
0.04 %
(as of May 21)
Anti-Malarial - Market Share
0.03 %
(as of Nov 21)
Blood Related - Market Share
0.01 %
(as of Jul 22)
Cardiovascular - Market Share
0.02 %
(as of Nov 21)
Dermatology - Market Share
0.04 %
(as of Aug 20)
Endocrinology - Market Share

Revenue mix

Product Wise Break-Up

Location Wise Break-Up

Operational Metrics

    Select a Metric
    • R&D as a % of Total Sales (%)

    Peer Comparison

    Brands

    Shapers

    Corporate Actions

    Consolidated
    DATE
    DETAILS
    Show More
    Show Less
    Show More
    Show Less

    Suppliers

    • ICE Make Refrigeration Ltd.
    • Zim Laboratories Ltd.

    FAQs on Gufic Biosciences Ltd. Business

    Gufic Biosciences Limited, a public company from India, specializes in manufacturing and marketing active pharmaceutical ingredients and generic pharmaceuticals.

    Gufic Biosciences major competitors are Orchid Pharma, Unichem Lab, Guj. Themis Biosyn, Sequent Scientific, Zota Health Care, Indoco Remedies, Panacea Biotec.
    Market Cap of Gufic Biosciences is ₹3,653 Crs.
    While the median market cap of its peers are ₹3,595 Crs.

    Gufic Biosciences seems to be less financially stable compared to its competitors.
    Altman Z score of Gufic Biosciences is 5.95 and is ranked 4 out of its 8 competitors.

    Company Filing

    2025 2024 2023 2022 2021 2020 2019 2018 2017 2016 2015 2014 2013 2012 2011 2010
    Annual Report FY25 FY24 FY23 FY22 FY21 FY20 FY19 FY18 FY17 FY16 FY15 FY14 FY13 FY12 FY11 FY10
    Earnings Release Jun Sep Dec
    Investor Presentation May Aug Feb Mar Jun Sep Dec Mar Jun Sep Dec Mar Jun Aug Sep Mar Jun Dec Mar Sep
    Conference Call Mar Mar Jun Sep Dec Mar Jun Sep Dec Mar Jun Sep Dec Jun Dec
    Conference Call SummaryCon Call Summary

    Discussions & Analysis

    Ideas Dashboard
    Results
    Timeline
    Watchlist
    Portfolio
    Alerts
    Stock Screener
    Market
    Raw Material